Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II first-line toripalimab plus antiangiogenic chemoradiotherapy for advanced malignant melanoma
ChiCTR2200062880Phase 2Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Aug 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab, bevacizumab and paclitaxel in melanoma, sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: objective response rate and disease control rate. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
toripalimabbevacizumabpaclitaxel
03
Conditions
melanoma
Beyond the preview
Go deeper on ChiCTR2200062880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062880.